Top

Published in:

Open Access 01-12-2014 | Review

Homoharringtonine and omacetaxine for myeloid hematological malignancies

Authors: Shuqing Lü, Jianmin Wang

Published in: Journal of Hematology & Oncology | Issue 1/2014

Abstract

Homoharringtonine (HHT), a plant alkaloid with antitumor properties originally identified nearly 40 years ago, has a unique mechanism of action by preventing the initial elongation step of protein synthesis. HHT has been used widely in China for the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Omacetaxine, a semisynthetic form of HHT, with excellent bioavailability by the subcutaneous route, has recently been approved by FDA of the United States for the treatment of CML refractory to tyrosine kinase inhibitors. This review summarized preclinical and clinical development of HHT and omacetaxine for myeloid hematological malignancies.

Available only for authorised users

Cooperative Study Group of Zhe Jiang province for Cephalotaxus fortune Hook: Clinical studies of alkaloids from cephalotaxus fortune Hook. Zhe Jiang Zhong Liu Tong Xun. 1976, 2: 14-

Paudler WW, Kerley GI, McKay J: The alkaloids of cephalotaxus drupacea and cephalotaxusfortunei. J Org Chem. 1963, 28: 2194-2197. 10.1021/jo01044a010.CrossRef

Powell RG, Smith CR: Structure of cephalotaxine and related alkaloids. Tetrahedron Lett. 1969, 46: 4081-4084.CrossRef

Powell RG, Weislede D, Smith CR: Antitumor alkaloids from cephalotaxus harringtonia: structure and activity. J Pharm Sci. 1972, 61: 1227-1230. 10.1002/jps.2600610812.CrossRefPubMed

Shanghai Institute of Materia Medica, Shanghai Leukemia Coordinating Group, Provincial People's Hospital of Fukien and Chekiang Cephalotaxus Research Coordinating Group of China: Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J (Engl). 1976, 2: 263-272.

Institute of Materia Medica: The antitumor effects and pharmacologic actions of harringtonine. Chinese Med J. 1977, 3: 319-324.

Chinese People’s Liberation Army, 187th Hospital: Homoharringtonine in the treatment of leukemias: clinical analysis of 72 cases. Chinese Med J. 1978, 3: 163-166.

Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP: Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984, 68: 1085-1091.PubMed

Coonley CJ, Warrell RP, Young CW: Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep. 1983, 67: 693-696.PubMed

10.

Zhang ZY, Hou CH, Zhu YF: A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine. Chinese J Intern Med. 1986, 25: 156-157. 190

11.

O’Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M: Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995, 86: 3322-3326.PubMed

12.

Zheng BG, Luo XS, Zhou YH, Zheng ZY, Shen YP, Lin SY, Hu ZP: The treatment of HA regimen in 34 patients with acute non-lymphocytic leukemia. Chin J Hematol. 1989, 10: 405-406.

13.

Cao PS, Liu X: The treatment of harringtonine in 13 patients with myelodysplastic syndrome. Chin J Hematol. 1990, 11: 425-

14.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2: 561-566. 10.1038/nm0596-561.CrossRefPubMed

15.

Robin J, Dhal R, Dujardin G, Girodier L, Mevellec L, Poutot S: The first semi-synthesis of enantiopure homoharringtonine via anhydro homoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett. 1999, 40: 2931-2934. 10.1016/S0040-4039(99)00327-5.CrossRef

16.

Fresno M, Jiménez A, Vázquez D: Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977, 72: 323-330. 10.1111/j.1432-1033.1977.tb11256.x.CrossRefPubMed

17.

Huang MT: Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol. 1975, 11: 511-519.PubMed

18.

Gurel G, Blaha G, Moore PB, Steitz TA: U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol. 2009, 389: 146-156. 10.1016/j.jmb.2009.04.005.PubMedCentralCrossRefPubMed

19.

Chen R, Gandhi V, Plunkett W: A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006, 66: 10959-10966. 10.1158/0008-5472.CAN-06-1216.CrossRefPubMed

20.

Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka R, Andreeff M, Taniwaki M, Maekawa T: Anti-myeloma effect of homoharringtonine with concomitant targeting of the myelomapromoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol. 2008, 87: 507-515. 10.1007/s12185-008-0081-8.CrossRefPubMed

21.

Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z, Legrand O, Marie JP: Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006, 5: 723-731. 10.1158/1535-7163.MCT-05-0164.CrossRefPubMed

22.

Mai WY, Lin MF: Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Chin Med J (Engl). 2005, 118: 487-492.

23.

Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T: ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol. 2008, 140: 181-190.PubMed

24.

Lou Y, Jin J, Xu W, Tong X: Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol. 2004, 76: 199-204. 10.1002/ajh.20100.CrossRef

25.

Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J: c-Myc and eIF4F are components of a feed forward loop that links transcription and translation. Cancer Res. 2008, 68: 5326-5334. 10.1158/0008-5472.CAN-07-5876. 5322CrossRefPubMed

26.

Lin CJ, Malina A, Pelletier J: c-Myc and eIF4F constitute a feed forward loop that regulates cell growth: implications for anticancer therapy. Cancer Res. 2009, 69: 7491-7494. 10.1158/0008-5472.CAN-09-0813.CrossRefPubMed

27.

Cai Z, Bao HY, Ludwig WD, Wuchter C: Expression and significance of apoptosis protein inhibitor survivin and XIAP, in patients with myelodysplastic syndromes and in the cell line MUTZ-1. Chinese J Hematol. 2004, 25: 26-30.

28.

Hu J, He D, Xue X, Gao L, Wu W, Han X, Cai Z: Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Leuk Lymphoma. 2007, 48: 964-977. 10.1080/10428190701216360.CrossRef

29.

Tong H, Ren Y, Zhang F, Jin J: Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. Eur J Haematol. 2008, 81: 259-266. 10.1111/j.1600-0609.2008.01116.x.CrossRefPubMed

30.

Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR: The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009, 113: 4656-4666. 10.1182/blood-2008-09-175430.PubMedCentralCrossRefPubMed

31.

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G: Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155expressions in acute myeloid leukemia. J Hematol Oncol. 2013, 6: 21-10.1186/1756-8722-6-21.PubMedCentralCrossRefPubMed

32.

Visani G, Russo D, Ottaviani E, Tosi P, Damiani D, Michelutti A, Manfroi S, Baccarani M, Tura S: Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on in vitro growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia. 1997, 11: 624-628. 10.1038/sj.leu.2400608.CrossRefPubMed

33.

Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003, 102: 276-283. 10.1182/blood-2002-09-2896.CrossRefPubMed

34.

Wang H, Guo Z, Ji S: Homoharringtonine induces apoptosis of K562 cells through inhibition of P210bcr/abl. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2000, 8: 287-289.PubMed

35.

Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S: Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia. 2009, 23: 1446-1454. 10.1038/leu.2009.52.PubMedCentralCrossRefPubMed

36.

Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV: Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia. 2002, 16: 2349-2357. 10.1038/sj.leu.2402775.CrossRefPubMed

37.

Jorgensen HG, Holyoake TL: Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans. 2007, 35 (Pt 5): 1347-1351.CrossRefPubMed

38.

Allan EK, Holyoake TL, Craig AR, Jørgensen HG: Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia. 2011, 25: 985-994. 10.1038/leu.2011.55.CrossRefPubMed

39.

Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007, 12: 528-541. 10.1016/j.ccr.2007.11.003.PubMedCentralCrossRefPubMed

40.

Hu Y, Chen Y, Douglas L, Li S: Beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009, 23: 109-116. 10.1038/leu.2008.262.CrossRefPubMed

41.

Klag T, Hartel N, Schenk T, Craig AR, Hochhaus A, Rosee PL: Downregulation of the common cytokine receptor subunit beta c by omacetaxine in CML: a potential molecular mechanism to overcome cytokine-mediated resistance against BCR-ABL-inhibitors. Blood. 2009, 114: 3256-Abs

42.

Shen JP, Yang H, Ni WM, Qian WB: Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012, 41: 485-490.PubMed

43.

Huang ZM, Chen M, Lü LH, Huang SH, Chen ZZ, Liang YY: A report of 33 cases of chronic granulocytic leukemia treated with harringtonine. Fu Jian Yi Ke Da Xue Xue Bao. 1998, 32: 383-384.

44.

Li YF, Wang CL, Ding BH, Zhu JB, Zheng ST, Yu L, Qian MS: The long-term follow-up results of chronic granulocytic leukemia treated with homoharringtonine. Chin J Hematol. 2004, 25: 378-379.

45.

Li CL, Yu XJ: The long-term results of 41 cases with chronic granulocytic leukemia treated with homoharringtonine. Bai Xue Bing. Lin Ba Liu. 2008, 17: 142-143.

46.

Neidhart JA, Young DC, Derocher D, Metz EN: Phase I trial of homoharringtonine. Cancer Treat Rep. 1983, 67: 801-804.PubMed

47.

Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O’Brien S: Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000, 18: 3513-3521.PubMed

48.

Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA, Cancer and Leukemia Group B: A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009, 63: 859-864. 10.1007/s00280-008-0805-8.CrossRefPubMed

49.

O’Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM: Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003, 98: 888-893. 10.1002/cncr.11620.CrossRefPubMed

50.

He ZG, Hou LJ, Xu JB: The clinic study of therapy in the chronic myelocytic leukemia-chronic phase by AS2O3 combined with homoharringtonine. J Med Res. 2008, 37: 56-57.

51.

Price KE, Saleem N, Lee G, Steinberg M: Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther. 2013, 6: 1111-1118.PubMedCentralPubMed

52.

Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF: Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer. 2005, 103: 1850-1855. 10.1002/cncr.20975.CrossRefPubMed

53.

Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O’Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J: Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007, 109: 248-255. 10.1002/cncr.22398.CrossRefPubMed

54.

Legros L, Hayette S, Nicolini FE, Raynaud S, Chabane K, Magaud JP, Cassuto JP, Michallet M: BCR-ABL (T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?. Leukemia. 2007, 21: 2204-2206. 10.1038/sj.leu.2404772.CrossRefPubMed

55.

Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S, Nicolas-Virelizier E, Michallet M, Tigaud I, Magaud JP, Turhan A, Guilhot F, Hayette S: The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. Clin Lymphoma Myeloma Leuk. 2010, 10: 394-399. 10.3816/CLML.2010.n.073.CrossRefPubMed

56.

Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H, Omacetaxine 202Study Group: Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012, 120: 2573-2580. 10.1182/blood-2012-03-415307.CrossRefPubMed

57.

Wang JM, Zhao ZY, Liu MX, Ju GD, Xu ZH, Zhang P: Clinical observation of low-dose harringtonine combination regimen in the treatment of acute non-lymphocytic leukemia. Chin J Hematol. 1989, 10: 137-

58.

Huang CL, Qiao QD, Tao L: The effects observation of low-dose Ara-c and harringtonine combination regimen in the treatment of acute leukemia. Chin J Intern Med. 1989, 28: 239-

59.

Bian SG, Hao YS, Wang ZC: Study of the treatment of adult acute non-lymphocytic leukemia. Chin J Hematol. 1993, 14: 59-62.

60.

Fu YH, Liu YZ: 106 cases of acute myeloid leukemia treated with HA or DA regimen. Hu Nan Yi Xue. 2001, 18: 390-

61.

Yang M, Chen Q, Chen Y, Pan HP: The effects comparison of homoharringtonine and daunorubicin in the treatment of 56 patients with acute myeloid leukemia. Acta Acad Med ZUNYI. 2005, 28: 345-346.

62.

Xue YP, Bian SG, Meng QX, Mi YC, Yang DG: Clinical observation of HAD regien in adult acute myeloid leukemia treatment. Chin J Hematol. 1995, 16: 59-61.

63.

Xiao Z, Xue H, Li R, Zhang L, Yu M, Hao Y: The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia. Am J Hematol. 2008, 83: 203-205. 10.1002/ajh.21068.CrossRefPubMed

64.

Wan CC, Guo RC, Zhang ZH, Xia YJ: The efficacy observation of HAA regimen in acute myeloid leukemia. Lin Chuang Xue Ye Xue Za Zhi. 1997, 10: 92-

65.

Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL: Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia. 2006, 20: 1361-10.1038/sj.leu.2404287. 136CrossRefPubMed

66.

Song YP, Tong Y, Qian WB, Mai WY, Meng HT, Qian JJ, Tong HY, Huang J, Mao LP, Xu WL, Jin J: The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia. Chin J Intern Med. 2011, 50: 48-51.

67.

Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ: Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013, 14: 599-608. 10.1016/S1470-2045(13)70152-9.CrossRefPubMed

68.

Xu JM, Du Y, Zhang LL, Zhong WY, Xue LY: The treatment of all-transretinoic acid and low-dose homoharringtonine in acute promyelocytic leukemia. Shan Xi Bai Xue Bing. 1992, 1: 156-158.

69.

Liu QC ZBR, Zhang FX, Guo LH, Ge XR: The combination of all-transretinoic acid and low-dose homoharringtonine in the treatment of acute promyelocytic leukemia. Chin J Intern Med. 2000, 39: 475-476.

70.

Lin WQ, Zheng HY: The clinical analysis of all-transretinoic acid and As2o3 in combination with homoharringtonine for acute promyelocytic leukemia. China Prac Med. 2009, 4: 153-154.

71.

Cao LP: The combination of arsenious acid, retinoic acid, homoharringtonine and cytarabine in the treatment of 20 cases with acute promyelocytic leukemia. Bai Xue Bing. Lin Ba Liu. 2006, 15: 291-292.

72.

Yuan Y, Li W, Lin D, Mi YC, Wang Y, Wei H, Liu BC, Zhou CL, Liu KQ, Wang JY, Wei SN, Gong BF, Zhao XL, Sun MY, Wang JX: Outcome of acute promyelocytic leukemia with homoharringtonine and ATRA. Chin J Hematol. 2011, 32: 752-757.

73.

Pei RZ, Li SY, Zhang PS, Ma JX, Liu XH, Du XH, Chen D, Sha KY, Chen LG, Cao JJ, Zhuang XX, Wu JY, Lin L, Fan Z, Ye PP, Tang SH, Zhang BB, Shi XW: Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia. Chin J Hematol. 2013, 34: 144-148.

74.

Liu KQ, Wei H, Wang HJ, Zhou CL, Liu BC, Lin D, Li W, Wang JY, Wei SN, Gong BF, Zhang GJ, Zhao X, Zhao XL, Mi YC, Wang JX: Comparison of homoharringtonine and daunorubicin cardiotoxicitv in adults with acute promyelocytic leukemia. J Clin Med Pract. 2012, 16: 10-12. 17

75.

Meng FY, Xu B, Zhou SY: Treatment of HA combination with etoposide or VM-26 in high-risk and refractory adult acute myeloid leukemia. Bai Xue Bing. 1999, 8: 142-143.

76.

Wei XD, Liu YY, Zhang LN, Wang P, Zhang YL, Zhu XH, Song YP: The comparison of efficiencies of CHG and CAG priming regimens in treatment of relapsed or fractory acute myeloid leukemia. Chin J Hematol. 2006, 27: 64-

77.

Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, Wang JL: Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2008, 83: 185-188. 10.1002/ajh.20903.CrossRefPubMed

78.

Ji YY, Zhang WG, Chen YX, Zhao XM, He AL, Liu J, Wang JL, Wang FX, Zhang PY, Zhang WJ: Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010, 18: 213-218.PubMed

79.

Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, Liu J, Ma XR: Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol. 2011, 137: 997-1003. 10.1007/s00432-010-0947-z.CrossRefPubMed

80.

Liu DB, Zhang YJ, Zhu XP, Xu WQ, Sun L, Luo YL: The comparison of efficiencies of HAG and HA regimens in treatment of elderly acute myeloid leukemia. Fu Jian Yi Ke Da Xue Xue Bao. 2006, 40: 274-276.

81.

Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P: Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia. 1992, 6: 1189-1191.PubMed

82.

Ji SY, Zhang F, Yang YL, Ding K: The treatment of low dose harringtonine in 14 patients with myelodysplastic syndrome. Ban Bu Yi Xue Yuan Xue Bao. 1997, 22: 253-

83.

Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA: Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 1996, 10: 40-42.PubMed

84.

Shu HE, Li WG, Ge SB: Analysis of HAG regimen in the treatment of 28 patients with MDS-RAEB. Zhongguo Wu Zhen Xue Za Zhi. 2007, 7: 331-332.

85.

Su JY, Chang CK, Zhang X, Zhou LY, Song LQ, Xu L, Wu LY, He Q, Li X: Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009, 17: 459-463.PubMed

86.

Wu L, Li X, Su J, Chang C, He Q, Zhang X, Xu L, Song L, Pu Q: Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma. 2009, 50: 1461-1467. 10.1080/10428190903096719.CrossRefPubMed

87.

Wu L, Li X, Su J, He Q, Zhang X, Chang C, Pu Q: Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AMLtransformed from MDS. J Cancer Res Clin Oncol. 2011, 137: 1563-1569. 10.1007/s00432-011-1020-2.CrossRefPubMed

88.

Brown D, Michaels S: Design and evaluation of oral delivery dosage forms of homoharringtonine [abstract]. Proc 98th Annual Meet Am Assoc Cancer Res. 2007, 48: 4730-abstract

Title: Homoharringtonine and omacetaxine for myeloid hematological malignancies
Authors: Shuqing Lü
Jianmin Wang
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2014
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-7-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins

Circulating miRNAs in cancer: from detection to therapy

Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding

IMP3 signatures of fallopian tube: a risk for pelvic serous cancers

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer